Ozempic increases risk of debilitating eye condition: studies

NAION risk and how big it is

• Discussion centers on semaglutide (Ozempic/Rybelsus, possibly Wegovy) and a rare eye condition: non‑arteritic anterior ischemic optic neuropathy (NAION), which causes sudden, usually painless vision loss in one eye.
• Studies report roughly a doubling of NAION risk in type 2 diabetics on once‑weekly semaglutide.
• Absolute risk remains low: around 0.2 cases per 1,000 person‑years, with ~1.5–2.5 additional cases per 10,000 treated people per year.
• Some argue that “risk doubling” sounds alarming without base rates; others note that even rare doubled risks merit attention if mechanisms are unknown.

Causality, study design, and data

• Both Danish studies are observational cohort designs; commenters stress they cannot prove causation.
• One view: “correlation is not causation” is overused and can be weaponized to dismiss legitimate signals; still, more research is needed, especially given NAION’s rarity.
• Concerns raised about confounding: semaglutide users may be sicker on average.
• One commenter notes NAION incidence peaks align more with COVID timing than with semaglutide uptake, suggesting possible alternative explanations (speculative within thread).

Context: diabetes, obesity, and relative risk

• Multiple comments emphasize that untreated type 2 diabetes and obesity already carry high risks (including blindness, cardiovascular disease, kidney damage).
• Consensus in the thread: any added NAION risk from semaglutide is likely much smaller than the overall health risks from diabetes/obesity.

Use for weight loss vs diabetes

• Studies discussed focus on type 2 diabetics; impact on non‑diabetic weight‑loss users is labeled “unclear.”
• Some argue current media coverage should draw a clearer distinction, given explosive off‑label/weight‑loss use.

Side effects, benefits, and long‑term uncertainty

• GLP‑1 agonists are said to have relatively low intrinsic hypoglycemia risk unless combined with other diabetic drugs.
• Reported benefits go beyond weight loss: reduced cravings/addictive behaviors, improved sleep and functioning, and possible anti‑inflammatory and neuroprotective effects (all based on anecdotes and early studies cited in the thread).
• Others warn of GI and other side effects, unknown decades‑long safety, and the likelihood of weight regain after stopping.

Ethical and cultural debate

• Strong clash between:
  • A camp viewing GLP‑1 use for obesity as an acceptable, even transformative medical tool.
  • A camp framing obesity mainly as personal responsibility and seeing drugs as “easy way out” with “nature’s price.”
• Counter‑arguments stress addiction‑like dynamics of overeating, biological variability, and the legitimacy of medical “shortcuts” when they improve health.